Anti-Ras (mutation Q61H) Monoclonal Antibody, clone XH110

Introduction Coronavirus disease 2019 (COVID-19) has the characteristics of high transmission, diverse clinical manifestations, and a long incubation period. In addition to infecting the respiratory system, COVID-19 also has adverse effects on the cardiovascular system. COVID-19 causes acute myocardial injuries, as well as chronic damage to the cardiovascular system. Areas covered The present review is aimed at providing current information on COVID-19 and the cardiovascular system. PubMed, Scopus, Science direct, and Google Scholar were searched. Expert opinion It is suggested that heart injury caused by COVID-19 infection might be an important cause of severe clinical phenotypes or adverse events in affected patients. Myocardial damage is closely related to the severity of the disease and even the prognosis in patients with COVID-19. In addition to disorders that are caused by COVID-19 on the cardiovascular system, more protection should be employed for patients with preexisting cardiovascular disease (CVD). Hence, it is very important that once relevant symptoms appear, patients with COVID-19 be rapidly treated to reduce mortality. Thus, early measurements of cardiac damageviabiomarkers following hospitalization for COVID-19 infections in a patient with preexisting CVD are recommended, together with careful monitoring of any myocardial injury that might be caused by the infection. ICU: An intensive care unit;2019-nCoV: 2019 novel coronavirus;ACEI: ACE inhibitor;ACS: Acute coronary syndrome;ARDS: Acute respiratory distress syndrome;AT(1)R: Ang II type 1 receptor;ATP: Adenosine triphosphate;ACC: American College of Cardiology;ACE: Angiotensin converting enzyme;Ang II: Angiotensin II;ARB: Angiotensin II receptor blocker;AV block: Atrioventricular block;CAD: Coronary artery disease;CVD: Cardiovascular disease;CT: Computerized tomography;CHF: Congestive heart failure;CHD: Coronary heart disease;CK-MB: Creatine kinase isoenzyme-MB;CRP: C-reactive protein;cTnI: Cardiac troponin I;EAT: Epicardial adipose tissue;ECMO: Extracorporeal membrane oxygenation;FDA: Food and Drug Administration;G-CSF: Granulocyte colony-stimulating factor;HFrEF: HF with a reduced ejection fraction;synhACE2: Human isoform of ACE2;IL: Interleukin;IABP: Intra-aortic balloon counterpulsation;IP10: Interferon gamma-induced protein 10 kDa;LPC: Lysophosphatidylcholine;Mas: Mitochondrial assembly receptor;MCP1: Monocyte chemoattractant protein-1;MERS: Middle East respiratory syndrome;MIP1a: macrophage inflammatory protein 1a:MOF: Multiple organ failure;MI: Myocardial infarction;MRI: Magnetic resonance imaging;MYO: Myohe-moglobin;NT-proBNP: N-terminal pro-brain natriuretic peptide;PCPS: Percutaneous cardiopulmonary assistance;rhACE2: Recombinant human ACE2;SARS: Severe acute respiratory syndrome;Th: T helper;RAS: Renin-angiotensin system;TNF-alpha: Tumor necrosis factor-alpha;WHO: World Health Organization.

Oncogenic RAS proteins, involved in similar to 30% of human tumors, are molecular switches of various signal transduction pathways. Here we apply a new protocol for the NMR study of KRAS in its (inactive) GDP- and (activated) GTP-bound form, allowing a comprehensive analysis of the backbone dynamics of its WT-, G12C- and G12D variants. We found that Tyr32 shows opposite mobility with respect to the backbone of its surroundings: it is more flexible in the GDP-bound form while more rigid in GTP-complexes (especially in WT- and G12D-GTP). Using the G12C/Y32F double mutant, we showed that the presence of the hydroxyl group of Tyr32 has a marked effect on the G12C-KRAS-GTP system as well. Molecular dynamics simulations indicate that Tyr32 is linked to the gamma-phosphate of GTP in the activated states - an arrangement shown, using QM/MM calculations, to support catalysis. Anchoring Tyr32 to the gamma-phosphate contributes to the capture of the catalytic waters participating in the intrinsic hydrolysis of GTP and supports a simultaneous triple proton transfer step (catalytic water -> assisting water -> Tyr32 -> O1G of the gamma-phosphate) leading to straightforward product formation. The coupled flip of negatively charged residues of switch I toward the inside of the effector binding pocket potentiates ligand recognition, while positioning of Thr35 to enter the coordination sphere of the Mg(2+)widens the pocket. Position 12 mutations do not disturb the capture of Tyr32 by the gamma-phosphate, but (partially) displace Gln61, which opens up the catalytic pocket and destabilizes catalytic water molecules thus impairing intrinsic hydrolysis.